1. Home
  2. PRVA vs HCM Comparison

PRVA vs HCM Comparison

Compare PRVA & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Privia Health Group Inc.

PRVA

Privia Health Group Inc.

N/A

Current Price

$20.40

Market Cap

3.0B

Sector

Technology

ML Signal

N/A

Logo HUTCHMED (China) Limited

HCM

HUTCHMED (China) Limited

HOLD

Current Price

$12.83

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRVA
HCM
Founded
2007
2000
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.3B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
PRVA
HCM
Price
$20.40
$12.83
Analyst Decision
Buy
Sell
Analyst Count
12
1
Target Price
$31.17
$13.75
AVG Volume (30 Days)
990.2K
85.3K
Earning Date
05-07-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
63.64
N/A
EPS
0.09
N/A
Revenue
$2,122,842,000.00
N/A
Revenue This Year
$18.19
$20.60
Revenue Next Year
$10.72
$15.62
P/E Ratio
$226.89
$5.49
Revenue Growth
22.26
N/A
52 Week Low
$19.53
$9.77
52 Week High
$28.82
$17.79

Technical Indicators

Market Signals
Indicator
PRVA
HCM
Relative Strength Index (RSI) 27.73 57.52
Support Level $19.62 $12.99
Resistance Level $23.99 $15.22
Average True Range (ATR) 0.52 0.30
MACD 0.08 0.08
Stochastic Oscillator 11.70 53.07

Price Performance

Historical Comparison
PRVA
HCM

About PRVA Privia Health Group Inc.

Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.

About HCM HUTCHMED (China) Limited

HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.

Share on Social Networks: